Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Telix Pharmaceuticals.
RELATED STOCKHEAD STORIES
Health & Biotech
Health Check: Half-price sale as brokers ring the bell on Neuren shares
Health & Biotech
Health Check: You’re rehired! The Trump administration’s FDA staffing ‘fiasco’ puts sector in choppy, unchartered waters
Health & Biotech
Biocurious: With Mayne Pharmaceuticals under takeover offer, who’s next?
Health & Biotech
Health Check: After an ‘extraordinary’ year, analysts reckon Telix has a lot more tiger in the tank
News
Closing Bell: ASX stumbles through a forgettable week as banks drag; Austal at five-year high
News
Lunch Wrap: Domain soars 40pc on CoStar bid; GYG tumbles despite solid half
Health & Biotech
Biocurious: Hut Hut Hut! The growing list of ASX biotechs waiting for the FDA to call the start of play
Health & Biotech
ASX Quarterly Health Wrap: Bioxyne revenue up 77%, Radiopharm lists on Nasdaq
Health & Biotech
Biocurious: Lung imager Cyclopharm is breathing easy in the US market
News
ASX Lunch Wrap: Volatile morning for stocks; gold soars and Bitcoin breaks $101k
Health & Biotech
Scott Power: Telix achieves sustained growth; Pro Medicus wins another contract
Health & Biotech
Health Check: Telix to acquire next-gen therapeutics and biologics platform
Health & Biotech
Biocurious: With its pre-budget ‘wish list’, Ausbiotech prepares to bat for the sector in Canberra
Health & Biotech
Health Check: Local biotech starred in 2024, but the rising tide did not lift all boats
Health & Biotech
ASX healthcare 2024 winners and losers, plus what’s next for 2025
Health & Biotech
Health Check: Telix CEO gets pay bump as company files for US kidney imaging approval
Health & Biotech
